MedTrace Logo

Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment

NCT00938886 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2017-05-15

Study results available
· View outcomes & findings →

Summary

To test whether naltrexone compared to placebo can reduce heavy drinking and improve smoking cessation outcomes in heavy drinkers seeking smoking cessation treatment.

Conditions

  • Hazardous Drinking
  • Cigarette Smoking

Interventions

DRUG

Naltrexone

Daily 50 mg naltrexone

DRUG

Placebo

Matched naltrexone placebo

Sponsors & Collaborators

  • Brown University

    lead OTHER

Principal Investigators

  • Christopher W. Kahler, Ph.D. · Brown University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2015-11-30
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00938886 on ClinicalTrials.gov